Patterns of on-treatment cardiac adverse events within three clinical trials of adjuvant anthracycline-based chemotherapy.
CONCLUSION: On-treatment cardiac events are not uncommon during adjuvant chemotherapy for early breast cancer. Higher dose of anthracyclines and higher body mass index are associated with a higher risk of on-treatment cardiac events.
PMID: 29882200 [PubMed - as supplied by publisher]
Source: Breast Cancer - Category: Cancer & Oncology Authors: Abdel-Rahman O Tags: Breast Cancer Source Type: research
More News: Arrhythmia | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Men | Menopause | Study | Toxicology